TrialHepatology (Baltimore, Md.)2017

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.

Fred Poordad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.